Open AccessAnti‐native and recombinant myeloperoxidase monoclonals and human autoantibodies
Author(s) -
AUDRAIN M. A. P.,
BARANGER T. A. R.,
MOGUILEVSKI N.,
MARTIN S. J.,
DEVYS A.,
LOCKWOOD C. M.,
MULLER J. Y.,
ESNAULT V. L. M.
Publication year - 1997
Publication title -
clinical & experimental immunology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.329
H-Index - 135
eISSN - 1365-2249
pISSN - 0009-9104
DOI - 10.1046/j.1365-2249.1997.d01-895.x
Subject(s) - myeloperoxidase , epitope , autoantibody , recombinant dna , antibody , proteinase 3 , antigen , immunology , epitope mapping , biology , virology , inflammation , biochemistry , gene
Myeloperoxidase (MPO) is one of the main antigen targets of anti‐neutrophil cytoplasmic antibodies (ANCA) in systemic vasculitides. It has been suggested that anti‐MPO antibodies may recognize a single epitope on recombinant MPO. If confirmed on native MPO, this might allow specific therapeutic intervention with anti‐idiotypic MoAbs to prevent antibody–antigen interaction which is thought to cause activation of neutrophils and vasculitis. We searched for restriction in the epitope recognition profile in 50 patients with anti‐MPO autoantibodies, using both native and recombinant MPO. Mouse monoclonals were purified and tested in competition assays. At least four epitopes were identified on native MPO using these monoclonals and only two were conserved on recombinant MPO. We found that human MPO autoantibody response was not restricted to a single epitope on native MPO, as all sera tested did not show the same profile in competitive studies with monoclonals. Furthermure, 30% of human anti‐native MPO sera failed to recognize rMPO.